Skip to main content

UBS Sticks to Their Buy Rating for Boston Scientific (BSX)

Tipranks - Tipranks - Sat Mar 7, 5:42AM CST

UBS analyst Danielle Antalffy reiterated a Buy rating on Boston Scientific yesterday and set a price target of $120.00. The company’s shares closed yesterday at $72.99.

Claim 70% Off TipRanks Premium

According to TipRanks, Antalffy is a 3-star analyst with an average return of 2.4% and a 50.00% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Inspire Medical Systems, and Boston Scientific.

In addition to UBS, Boston Scientific also received a Buy from TD Cowen’s Josh Jennings in a report issued on March 4. However, on February 27, TipRanks – Google downgraded Boston Scientific (NYSE: BSX) to a Hold.

See the top stocks recommended by analysts >>

Based on Boston Scientific’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.29 billion and a net profit of $668 million. In comparison, last year the company earned a revenue of $4.56 billion and had a net profit of $566 million

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).